TheraCIM (nimotuzumab)

Our findings not only reveal a clinically relevant resistance mechanism to KRAS G12D inhibition but also provide a rational, effective combined strategy. Ultimately, the combination of HRS-4642 with nimotuzumab offers a promising therapeutic strategy for PDAC patients harboring KRAS G12D mutations, laying a foundation for advancing clinical research in overcoming resistance to KRAS G12D-targeted therapies.

The NTZ-AG regimen demonstrated meaningful anti-tumor activity and an acceptable safety profile as first-line therapy for unselected advanced pancreatic cancer patients, providing a rational basis for larger randomized controlled trials. This trial was registered at the Chinese Clinical Trial Register (ChiCTR) under the registration number ChiCTR2300072843 having URL https://www.chictr.org.cn/showprojEN.html?proj=198791.

P2, N=133, Recruiting, Zhejiang University | N=32 --> 133

P1/2, N=20, Active, not recruiting, West China Hospital | Trial primary completion date: Jan 2027 --> Aug 2026 | Recruiting --> Active, not recruiting

Oncologists should consider broad next-generation sequencing, including fusion detection, for patients with KRAS-wildtype PDAC. When an ALK fusion is identified, ALK inhibitor therapy can yield durable disease control.

P2, N=182, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Bevacizumab was associated with improved PFS, but not OS compared to standard therapy and other targeted therapies in newly diagnosed GBM patients. Exploratory subgroup findings suggested that nivolumab may be associated with less favorable OS and PFS estimates in MGMT-unmethylated patients. SUCRA rankings should be interpreted as exploratory because most interventions were supported by limited trial evidence. However, certain targeted drugs exhibit inadequate safety profiles, and careful risk-benefit assessment is required. Future research should further explore safer and more effective multi-targeted combination strategies to overcome GBM's survival bottleneck.

Among survivors, 45.5% reported high satisfaction with their QOL, and 84.8% did not experience weight loss. This combination therapy demonstrated promising efficacy and safety, suggesting it may be a viable treatment option for this patient population.

P2, N=76, Recruiting, Fifth Affiliated Hospital, Sun Yat-Sen University; Fifth Affiliated Hospital, Sun Yat-Sen University

P2, N=36, Recruiting, Langfang Campus of Chinese Academy of Medical Sciences Cancer Hospital; Langfang Campus of Chinese Academy of Medical Sciences Cancer Hospital

P=N/A, N=42, Chongqing Medical University First Affiliated Hospital; Chongqing Medical University First Affiliated Hospital

P2, N=28, The First Affiliated Hospital of Xiamen University; The First Affiliated Hospital of Xiamen University